Krystal Biotech (KRYS) Cash from Financing Activities (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Cash from Financing Activities data on file, last reported at -$10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 16.1% year-over-year to -$10.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.7 million (up 170.16% YoY), and the FY2025 full-year result was $8.7 million, down 67.78% from the prior year.
• Cash from Financing Activities slipped to -$10.5 million in Q1 2026, from $15.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $185.3 million in Q2 2023 to a low of -$12.5 million in Q1 2025.
• A 5-year average of $15.5 million and a median of $3.1 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 15527.14% in 2022 and plunged 217.79% in 2025, its largest moves.
• Tracing KRYS's Cash from Financing Activities over 5 years: stood at $3.1 million in 2022, then fell by 14.66% to $2.6 million in 2023, then fell by 7.29% to $2.4 million in 2024, then jumped by 545.22% to $15.7 million in 2025, then slumped by 166.76% to -$10.5 million in 2026.
• Business Quant data shows KRYS's Cash from Financing Activities at -$10.5 million in Q1 2026, $15.7 million in Q4 2025, and $3.7 million in Q3 2025.